Retired investment banker, private investor and executive (C-level) consultant. Investing/trading since 1981
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry but no pinks or OTCBBs on this board…
PVSP attorney letter out yesterday…
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174228877
Just checked OTCmarkets.com and noticed the attorney letter out yesterday…
https://www.otcmarkets.com/otcapi/company/financial-report/397385/content
Streeterville is bad news, a toxic debenture financier…
Do some homework on John Fife…
Underneath he was a very angry man which happens to celebrities who fall out of the limelight, a real shame…
R.I.P. O.J. Simpson, in memory of…
R.I.P. O.J. Simpson, in memory of…
R.I.P. O.J. Simpson, in memory of…
No pinks or OTCBBs on this board…
No pinks or OTCBBs on this board…
No pinks or OTCBBs on this board…
Ok, now you know…
No pinks or OTCBBs on this board…
Clean spaces pave the way for brighter futures!
— PCTL (@PCTL_) April 10, 2024
Discover how Hydrolyte® is revolutionizing cleanliness in educational facilities, ensuring safer environments for students and staff.
Shop us at https://t.co/uRh0Dls09N#StaySafe #Disinfection
#CleanSpaces #BrightFutures" pic.twitter.com/SMX9vjjxhp
Setting the Table for Safety!
Discover how Hydrolyte® is transforming restaurant hygiene, ensuring clean and safe dining experiences for all.
From tables to utensils, Hydrolyte® is the secret ingredient in keeping your favorite eateries spotless and sanitary.
Shop us at pctl.com
#RestaurantSafety #Hydrolyte #CleanDining" #cleaning #disinfecting
Setting the Table for Safety!
— PCTL (@PCTL_) April 10, 2024
Discover how Hydrolyte® is transforming restaurant hygiene, ensuring clean and safe dining experiences for all.
From tables to utensils, Hydrolyte® is the secret ingredient in keeping your favorite eateries spotless and sanitary.
Shop us at… pic.twitter.com/nMTJtswvEg
We all make mistakes…
Sorry but no pinks or OTCBBs on this board…
No pinks or OTCBBs on this board…
Hilarious!!
The Marc-Andre Fleury vs. Brandon Duhaime prank war continues 🤣pic.twitter.com/RF4YVYi7y9
— Caesars Sportsbook & Casino (@CaesarsSports) April 8, 2024
Still great pics…
unless we get another r/s
Unless Rory finds a way to pay off Streeterville’s toxic debenture, either through another equity financing or a dramatic increase in revenue to get Verb to self-sustaining positive cash flow, it’s almost a given another reverse split happens, in my opinion…
8-K filing regarding certain warrants expiring…
Item 8.01 Other Events.
On April 9, 2024, at 5:00 pm, New York City time, those certain warrants issued by Verb Technology Company, Inc. (the “Company”) pursuant to the terms of that certain Underwriting Agreement dated April 4, 2019, by and between the Company and A.G.P. / Alliance Global Partners, as representatives of the underwriters set forth therein, will expire by their terms.
Complete filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1566610/000149315224013788/form8-k.htm
Try harder, everyone here knows your true intentions…
https://ir.markertherapeutics.com/news-releases/news-release-details/principal-investigator-city-hope-national-medical-center-invited
PRINCIPAL INVESTIGATOR FROM CITY OF HOPE NATIONAL MEDICAL CENTER INVITED TO PRESENT CLINICAL DATA FROM MARKER THERAPEUTICS APOLLO STUDY AT 11TH GLOBAL SUMMIT ON HEMATOLOGIC MALIGNANCIES
April 8, 2024 at 7:00 AM EDT
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada
Study participants tolerated initial dose level well and demonstrated durable objective responses after MT-601 treatment
Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment
HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
The Phase 1 APOLLO study is investigating MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Marker previously reported that the first study participant tolerated the treatment well and achieved a complete response (CR) eight weeks after the second infusion of MT-601, which was maintained at the six months follow-up visit (PRESS RELEASE, SEPTEMBER 11, 2023). During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601. This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy. The participant relapsed within 90 days of CAR T cell therapy yet maintained a CR for at least nine months after treatment with MT-601, suggesting that response to MT-601 was more durable compared to CAR T cells in this study participant.
Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope. One of the study participants had transformed follicular NHL and failed a total of 12 lines of therapy including mosunetuzumab (bispecific antibody) for follicular NHL, and Yescarta (anti-CD19 CAR T cell therapy) after transformation into DLBCL. At the time of MT-601 administration, only follicular NHL persisted after the last treatment. Eight weeks after initial infusion with MT-601, this study participant achieved a CR and remains in CR three months following treatment with MT-601. The third patient treated at City of Hope as part of the APOLLO trial presented with DLBCL with cutaneous involvement only and was not eligible for CAR T cell therapy. When evaluated at eight weeks post-treatment, the study participant was in partial response with all lesions decreasing in size including one that has completely resolved.
Dr. Shouse also reported that treatment was well tolerated among all patients with no significant treatment-related adverse events including no reports of cytokine release syndrome (CRS) or immune-effector cell associated neurotoxicity syndrome (ICANS), and that all patients will continue to be monitored closely for long-term treatment effects and durability of response.
“We are encouraged by these clinical results and the potential impact of MT-601 in patients with lymphoma who have relapsed or are ineligible for CAR T cell therapy,” said Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA. "Observing objective responses in three out of three patients with lymphoma treated with MT-601 at our site is a remarkable and gratifying achievement and we are encouraged by the benefits this therapy has provided to our patients. I am honored to have been invited to showcase these data on MT-601 to leading experts in the field at the 11th Global Summit on Hematologic Malignancies.”
The therapeutic potential of MT-601 is further reinforced by non-clinical data demonstrating that MT-601 is able to eradicate lymphoma cells resistant to anti-CD19 CAR T cells (PRESS RELEASE, MAY 31, 2023).
CAR T cell therapy is associated with severe adverse events such as cytokine release syndrome or neurotoxicity, as well as the potential risk of inducing secondary cancers (U.S. FOOD AND DRUG ADMINISTRATION, NOVEMBER 28, 2023). MultiTAA-specific T cell therapies have been well-tolerated in clinical trials to date. Marker believes that multiTAA-specific T cells represent a safe alternative to CAR T cells due to their non-genetically engineered approach that selectively expands tumor-specific T cells from a patient’s/donor’s blood without the risk of mutagenesis.
“Although treatment with CD19-targeting CAR T cells is rapidly expanding among hematological malignancies, 40-60% of patients relapse within one year of therapy,” commented Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. “The sustained CR for nine months in our first study participant, who relapsed 90 days following CAR T cell treatment, indicates durable efficacy of MT-601 versus CAR T cell therapy in this participant.”
“Though the number of patients treated to date in our APOLLO study is quite small, observing objective responses in all three study participants treated at City of Hope is encouraging, and highlights the potential benefit of MT-601 in patients with lymphoma. We are continuing to enroll additional patients to hopefully reinforce these promising observations and look forward to treating more participants in this Phase 1 study,” concluded Dr. Vera.
Today we announced that one of our Principal Investigators was invited to present his experience from our #APOLLO study in patients with #lymphoma at the 11th Global Summit on Hematologic Malignancies.
— Marker Therapeutics, Inc. (@MRKRTherapeutic) April 8, 2024
For more information: https://t.co/BehXh5Myf2#immunotherapy #multiTAAs pic.twitter.com/HvIrf3coos
No pinks or OTCBBs on this board…
My pleasure… 😎
The triple top near 4.8% could be signaling higher yields ahead if broken to the upside…
Is anybody paying attention? pic.twitter.com/ioFQ4kZ8ZM
— Macro Charts (@MacroCharts) April 6, 2024
Is anybody paying attention? pic.twitter.com/ioFQ4kZ8ZM
— Macro Charts (@MacroCharts) April 6, 2024
From JPM:
— Macro Charts (@MacroCharts) March 13, 2024
• Momentum crowding flashing RED at 99.8%ile – fastest increase ever.
• Last seen at the peak of 2000 Tech Bubble.
• Equity investor positioning near prior highs.
• Momentum often becomes crowded – leading to inevitable momentum crash.
Stay nimble. pic.twitter.com/Nfg8WGebNr
Good luck with that…
You should take the time to read the annual report (10-K) and your delisting question(s) should be found…
https://www.sec.gov/Archives/edgar/data/1566610/000149315224012416/form10-k.htm
From page 20…
November 2, 2023 Notice
On November 2, 2023, we received a letter from The NASDAQ Stock Market advising that the Company did not meet the minimum $1.00 per share bid price requirement for continued inclusion on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Listing Rule 5550(a)(2). To demonstrate compliance with this requirement, the closing bid price of our common stock needs to be at least $1.00 per share for a minimum of 10 consecutive business days before April 30, 2024. In order to satisfy this requirement, the Company intends to continue actively monitoring the bid price for its common stock between now and April 30, 2024, and will consider available options to resolve the deficiency and regain compliance with the minimum bid price requirement, including, but not limited to seeking a six-month extension from The NASDAQ Stock Market in which to regain compliance.
Still here, trying to scare out cheap shares for yourself?
No, that filing has to do with delisting warrants, whichever ones they are I don’t know, yet…
Whomever wrote that must’ve been on acid…
Bada bing bada boom, lol…
Warrant expiration filing, I gotta look to see which ones…
https://www.sec.gov/Archives/edgar/data/1354457/000135445724000236/xslF25X02/primary_doc.xml